文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

英国临床骨质疏松症预防和治疗指南。

UK clinical guideline for the prevention and treatment of osteoporosis.

机构信息

Musculoskeletal Research Unit, Bristol Medical School, Learning and Research Building, University of Bristol, Southmead Hospital, Bristol, BS10 5NB, UK.

Royal United Hospital NHS Foundation Trust, Bath, UK.

出版信息

Arch Osteoporos. 2022 Apr 5;17(1):58. doi: 10.1007/s11657-022-01061-5.


DOI:10.1007/s11657-022-01061-5
PMID:35378630
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8979902/
Abstract

UNLABELLED: The National Osteoporosis Guideline Group (NOGG) has revised the UK guideline for the assessment and management of osteoporosis and the prevention of fragility fractures in postmenopausal women, and men age 50 years and older. Accredited by NICE, this guideline is relevant for all healthcare professionals involved in osteoporosis management. INTRODUCTION: The UK National Osteoporosis Guideline Group (NOGG) first produced a guideline on the prevention and treatment of osteoporosis in 2008, with updates in 2013 and 2017. This paper presents a major update of the guideline, the scope of which is to review the assessment and management of osteoporosis and the prevention of fragility fractures in postmenopausal women, and men age 50 years and older. METHODS: Where available, systematic reviews, meta-analyses and randomised controlled trials were used to provide the evidence base. Conclusions and recommendations were systematically graded according to the strength of the available evidence. RESULTS: Review of the evidence and recommendations are provided for the diagnosis of osteoporosis, fracture-risk assessment and intervention thresholds, management of vertebral fractures, non-pharmacological and pharmacological treatments, including duration and monitoring of anti-resorptive therapy, glucocorticoid-induced osteoporosis, and models of care for fracture prevention. Recommendations are made for training; service leads and commissioners of healthcare; and for review criteria for audit and quality improvement. CONCLUSION: The guideline, which has received accreditation from the National Institute of Health and Care Excellence (NICE), provides a comprehensive overview of the assessment and management of osteoporosis for all healthcare professionals involved in its management. This position paper has been endorsed by the International Osteoporosis Foundation and by the European Society for the Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.

摘要

未加标签:英国国家骨质疏松症指南小组(NOGG)修订了针对绝经后妇女和 50 岁及以上男性的骨质疏松症评估和管理以及脆性骨折预防的英国指南。该指南由 NICE 认可,与所有参与骨质疏松症管理的医疗保健专业人员都相关。

简介:英国国家骨质疏松症指南小组(NOGG)于 2008 年首次制定了预防和治疗骨质疏松症的指南,并于 2013 年和 2017 年进行了更新。本文提出了该指南的重大更新,其范围是审查绝经后妇女和 50 岁及以上男性的骨质疏松症评估和管理以及脆性骨折的预防。

方法:在有可用证据的情况下,使用系统评价、荟萃分析和随机对照试验来提供证据基础。根据可用证据的强度,对结论和建议进行系统分级。

结果:提供了关于骨质疏松症的诊断、骨折风险评估和干预阈值、椎体骨折的管理、非药物和药物治疗(包括抗吸收药物治疗的持续时间和监测)、糖皮质激素诱导的骨质疏松症以及骨折预防护理模式的建议。为培训、医疗保健服务负责人和委员会、以及审计和质量改进的审查标准提供了建议。

结论:该指南已获得国家卫生与保健卓越研究所(NICE)的认可,为所有参与骨质疏松症管理的医疗保健专业人员提供了骨质疏松症评估和管理的全面概述。本立场文件已得到国际骨质疏松基金会和欧洲骨质疏松症、骨关节炎和肌肉骨骼疾病临床和经济方面学会的认可。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8006/8979902/203f2e2602af/11657_2022_1061_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8006/8979902/315b32bb333c/11657_2022_1061_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8006/8979902/fa80da72e111/11657_2022_1061_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8006/8979902/9e613530c8e7/11657_2022_1061_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8006/8979902/327fb6392f81/11657_2022_1061_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8006/8979902/203f2e2602af/11657_2022_1061_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8006/8979902/315b32bb333c/11657_2022_1061_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8006/8979902/fa80da72e111/11657_2022_1061_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8006/8979902/9e613530c8e7/11657_2022_1061_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8006/8979902/327fb6392f81/11657_2022_1061_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8006/8979902/203f2e2602af/11657_2022_1061_Fig5_HTML.jpg

相似文献

[1]
UK clinical guideline for the prevention and treatment of osteoporosis.

Arch Osteoporos. 2022-4-5

[2]
UK clinical guideline for the prevention and treatment of osteoporosis.

Arch Osteoporos. 2017-4-19

[3]
Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013.

Maturitas. 2013-6-27

[4]
An assessment of intervention thresholds for very high fracture risk applied to the NOGG guidelines : A report for the National Osteoporosis Guideline Group (NOGG).

Osteoporos Int. 2021-10

[5]
Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK.

Maturitas. 2009-2-20

[6]
Summary of AHRQ's comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report.

J Manag Care Pharm. 2012-5

[7]
Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools.

Syst Rev. 2023-3-21

[8]
Access to fracture risk assessment by FRAX and linked National Osteoporosis Guideline Group (NOGG) guidance in the UK-an analysis of anonymous website activity.

Osteoporos Int. 2017-1

[9]
Prevention and treatment of glucocorticoid-induced osteoporosis in adults: recommendations from the European Calcified Tissue Society.

Eur J Endocrinol. 2024-11-27

[10]
A systematic review of intervention thresholds based on FRAX : A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation.

Arch Osteoporos. 2016-12

引用本文的文献

[1]
The cellular effect of intermittent PTH treatment on bone remodeling and modeling in humans-a histomorphometry centered scoping review.

Osteoporos Int. 2025-9-9

[2]
The 2024 UK clinical guideline for the prevention and treatment of osteoporosis.

Arch Osteoporos. 2025-9-8

[3]
Inpatient rehabilitation fracture liaison service (FLS) improves outcomes for secondary prevention of hip fractures.

Bone Rep. 2025-8-8

[4]
Surgical robot-guided unilateral percutaneous kyphoplasty: anatomical features and clinical efficacy of a modified transverse process-pedicle approach.

J Robot Surg. 2025-8-31

[5]
Maternal gut microbiota-derived daidzein prevents osteoporosis in female offspring following prenatal prednisone exposure.

Imeta. 2025-4-28

[6]
Mind the bone: a protocol for osteoporosis prophylaxis in patients with thyroid eye disease on intravenous methylprednisolone.

Eye (Lond). 2025-8-22

[7]
Risk of Osteoporosis and Anemia in Plant-Based Diets: A Systematic Review of Nutritional Deficiencies and Clinical Implications.

Cureus. 2025-7-21

[8]
Initiation of anti-osteoporosis medication following hip fracture in older adults: a systematic review and thematic synthesis of qualitative studies from patient and healthcare professional perspectives.

Age Ageing. 2025-8-1

[9]
Unraveling Ginsenoside Rg1's osteoprotective pathways in zebrafish models of glucocorticoid induced osteoporosis via transcriptomics.

Sci Rep. 2025-8-20

[10]
Lung-related risk factors associate with low bone mineral density in individuals with former tobacco exposure not meeting osteoporosis screening criteria.

Osteoporos Int. 2025-8-19

本文引用的文献

[1]
Strong, steady and straight: UK consensus statement on physical activity and exercise for osteoporosis.

Br J Sports Med. 2022-5-16

[2]
Assessment and management of imminent fracture risk in the setting of the fracture liaison service.

Osteoporos Int. 2022-6

[3]
SCOPE 2021: a new scorecard for osteoporosis in Europe.

Arch Osteoporos. 2021-6-2

[4]
The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its Discontinuation.

J Clin Endocrinol Metab. 2021-9-27

[5]
Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer.

J Bone Oncol. 2021-3-18

[6]
Short time horizons for fracture prediction tools: time for a rethink.

Osteoporos Int. 2021-6

[7]
An assessment of intervention thresholds for very high fracture risk applied to the NOGG guidelines : A report for the National Osteoporosis Guideline Group (NOGG).

Osteoporos Int. 2021-10

[8]
Developing a model Fracture Liaison Service consultation with patients, carers and clinicians: a Delphi survey to inform content of the iFraP complex consultation intervention.

Arch Osteoporos. 2021-3-24

[9]
The effect on subsequent fracture risk of age, sex, and prior fracture site by recency of prior fracture.

Osteoporos Int. 2021-8

[10]
Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden.

Osteoporos Int. 2021-3

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索